GlaxoSmithKline has started enrollment for phase III trials for its herpes zoster vaccine for the prevention of shingles.
This post was written by Hanson Search on August 27, 2010
Posted Under: Uncategorised
Posted Under: Uncategorised
The trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.
Merck’s Zostavax was the first approval of a shingles vaccine and came onto the market in 2006.
By Saphia Haddouche